Lexaria Bioscience Corp. LEXX
4.18 USD -0.60 (-12.55%)
At closeNov 12, 2026, 4:00 PM EST
4.18 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
4.02 Day range 4.44
2.43 52-week range 21.60
- YTD
- -54.86%
- 1 year
- -75.56%
News
benzinga.com Lexaria Bioscience Strikes Agreement With Undisclosed Pharma Firm To Investigate Lexaria's DehydraTECH Technology With One, More PharmCo Modules Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical…
thenewswire.com Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH Third pharmaceutical company relationship entered Kelowna, British Columbia – November 4, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global…
thenewswire.com Lexaria Celebrates its 70th Patent Award New patents awarded in the US, Canada, and Europe IP protection for treatments for Epilepsy, Diabetes, and Hypertension
benzinga.com Lexaria Bioscience Completes Enrollment And Continues Dosing On Schedule In Two Oral Semaglutide Pilot Study Comparing DehydraTECH Formulations To Wegovy Tablets Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with
thenewswire.com Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule Kelowna, BC – October 21, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that full enrollment has…
accessnewswire.com Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule KELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million. Senti Biosciences…- benzinga.com Lexaria Bioscience Announces Results From Animal Study GLP-1-A26-1 Evaluating Both DehydraTECH-CBD Compositions And DehydraTECH-Semaglutide; Unfortunately, The DHT-SEMA Concentrations In Brain Tissue Were All At Levels Below The Lower Limit Of Quantitation Of The Bioassay Utilized In This Study Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the
thenewswire.com Lexaria Announces Results From Animal Study GLP-1-A26-1 Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC – October 15, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a…- accessnewswire.com Lexaria Announces Results from Animal Study GLP-1-A26-1 Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
thenewswire.com GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery- accessnewswire.com GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
thenewswire.com Lexaria Updates Financial Position Kelowna, British Columbia – September 17, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is providing the…- accessnewswire.com Lexaria Updates Financial Position KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON)…
accessnewswire.com Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously…
thenewswire.com Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
benzinga.com Dow Tumbles 450 Points; US Small Business Sentiment Declines In August U.S. stocks fell Tuesday, led by a 450-point Dow drop; health care slid while energy rose. NFIB optimism weakened, oil and copper gained.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…
thenewswire.com Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds Kelowna, British Columbia – TheNewswire - September 8 , 2026 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today…
accessnewswire.com Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced…
thenewswire.com Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference Kelowna, British Columbia – September 4 , 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces…
benzinga.com Lexaria Bioscience Announces Australian Tax Office Pays AU$3.667M In Tax Rebate To Co. Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98…
thenewswire.com Lexaria Receives USD$2.6 Million Tax Rebate Payment Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate Kelowna, British Columbia – September 1 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the…- accessnewswire.com Lexaria Receives USD$2.6 Million Tax Rebate Payment Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"),…
benzinga.com Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry studyProprietary DehydraTECH 3.0 retatrutide tablet formulation…
accessnewswire.com DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
benzinga.com Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here's what investors need to know.
benzinga.com Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know Lexaria Bioscience shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
benzinga.com Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.The MTA details the conditions under which…
thenewswire.com Lexaria Enters a Material Transfer Agreement with PegBio Kelowna, British Columbia – TheNewswire - August 13, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million. Apimeds Pharmaceuticals…
- benzinga.com Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 0 percent. This is a 61.9 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
benzinga.com Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglutide Formulations To Wegovy, With Dosing Expected To Begin In Mid-June Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an…- benzinga.com Lexaria Bioscience Advances Human Study Of DehydraTECH-Semaglutide Versus Wegovy Tablets Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate…